Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

this interim analysis demonstrates that once-weekly subcutaneous semaglutide at a dose of 2.4 milligrams significantly improves liver histology in patients with MASH and moderate-to-advanced fibrosis.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Semaglutide and tirzepatide prescriptions for obesity are influenced by race, gender, social vulnerability, and urbanicity, with disparities in access and utilization. Despite increased ...

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...

Through transparent pricing, unlimited provider communication, and a lab-driven approach to dosage personalization, Sesame is making weight loss with compounded semaglutide more achievable for ...

Notably, the enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001). Enobosarm 6mg + semaglutide dose was not better than the Enobosarm ...